Novel targets for vaccines against tuberculosis

结核病疫苗的新靶点

• 批准号: 7386290
• 负责人: YURI BUSHKIN
• 金额: $ 18.98万
• 依托单位: UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-15 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7386290
• 关键词: Mycobacterium; alanine; bacterial proteins; cellular immunity; cytotoxic T lymphocyte; flow cytometry; genetically modified animals; glutamate ammonia ligase; immune response; laboratory mouse; oxidoreductase; polymerase chain reaction; technology /technique development; tuberculosis; vector vaccine

DESCRIPTION (provided by applicant): We have obtained evidence that in humans the profile of antigen-specific immune responses associated with active disease differs from that observed with latent infection. HLA-A2-restricted, Th1-type cytotoxic T lymphocyte responses against mycobacterial alanine dehydrogenase and glutamine synthetase can be detected only in non-vaccinated, tuberculin skin test-positive asymptomatic individuals but not in active tuberculosis patients. In the mouse lung, Th1 immunity is the principal cause for changes in the Mycobacterium tuberculosis growth from exponential to non-replicating persistence during infection. The shift in bacterial growth in response to Th1 immunity is accompanied by changes in the transcription pattern of immunodominant bacterial proteins. These data imply that some similarities may exist between antigenic profiles expressed by M. tuberculosis in human and mouse infections. We propose that T cell responses elicited against alanine dehydrogenase and glutamine synthetase are protective. Additionally, vaccination against these bacterial proteins expressed during chronic infection in mouse lung may be more effective than vaccination against other targets expressed predominantly at initial phase of infection. This hypothesis will be tested in a low-dose aerosol infection model employing mice transgenic for human HLA-A2 allele. The timing of expression of these bacterial proteins relative to the onset of Th1 immunity, and the kinetics of expression of antigen-specific T cell responses will be characterized during infection with M. tuberculosis. The protective potential of T cell-mediated immune responses against these proteins will be determined in DNA vaccinated and challenged mice. Finally, the molecular targets of polyclonal cytotoxic T lymphocyte responses elicited by DNA vaccines against the whole protein will be identified in challenged mice. This knowledge is expected to open a new approach in designs of vaccines against M. tuberculosis.

描述（由申请人提供）：我们已经获得证据表明，在人类中，与活动性疾病相关的抗原特异性免疫反应谱不同于观察到的潜伏性感染。hla - a2限制性、th1型细胞毒性T淋巴细胞对分枝杆菌丙氨酸脱氢酶和谷氨酰胺合成酶的反应只能在未接种疫苗、结核菌素皮肤试验阳性的无症状个体中检测到，而不能在活动性结核病患者中检测到。在小鼠肺中，Th1免疫是结核分枝杆菌在感染期间从指数生长到非复制持久性变化的主要原因。细菌生长对Th1免疫反应的转变伴随着免疫优势细菌蛋白转录模式的变化。这些数据暗示结核分枝杆菌在人类和小鼠感染中表达的抗原谱可能存在一些相似性。我们认为，针对丙氨酸脱氢酶和谷氨酰胺合成酶引发的T细胞反应具有保护作用。此外，针对小鼠肺部慢性感染期间表达的这些细菌蛋白接种疫苗可能比针对其他主要在感染初始阶段表达的靶标接种疫苗更有效。这一假设将在低剂量气溶胶感染模型中进行验证，该模型采用转基因人HLA-A2等位基因小鼠。在结核分枝杆菌感染期间，这些细菌蛋白的表达时间与Th1免疫的发病有关，抗原特异性T细胞反应的表达动力学将被表征。T细胞介导的免疫反应对这些蛋白质的保护潜力将在DNA接种和挑战小鼠中确定。最后，在小鼠中鉴定DNA疫苗引起的针对全蛋白的多克隆细胞毒性T淋巴细胞应答的分子靶点。这一知识有望为结核分枝杆菌疫苗的设计开辟一条新途径。